Gain Therapeutics(GANX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Conferences in Early Q4 2024 Initiation of Phase 1b Study of GT-02287 in Parkinson's Disease Patients Anticipated in Q4 2024 BETHESDA, Md., August 8, 2024 -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discov ...